TL;DR Gene and cell therapies can save lives, but they can also hit a health plan with a claim of $1 million to $3 million or more. Current examples often cited in the market include Zolgensma at about $2.1 million, Casgevy around $2.2 million, and Lyfgenia at about $3 million. Because many of these treatments are one-time therapies, the clinical promise is paired with a sharp upfront cost. Employers need a long-Term funding strategy, not a spreadsheet-only reaction after the claim arrives.
Key Takeaways
- A single gene or cell therapy claim can disrupt renewals, reserves, and cash flow.
- The therapy price is only one part of the total cost episode.
- Value-based contracts can tie payment to whether treatment works as expected.
- Carve-out programs and Stop-Loss coverage can limit financial shock, but both need close review.
- Biosimilars won’t fix gene therapy pricing, yet they can free up budget elsewhere.
- Strong planning requires finance, HR, and executive leaders to work from the same playbook.
A million-dollar therapy claim can feel like a lightning strike. It may be rare, but it can still split a benefits budget in half.
For C-suite, finance, and HR leaders, the challenge is twofold. You need to protect the plan’s financial health, and you need to protect access for the employee or dependent facing a serious condition. That is where JA’s view matters. Good benefits strategy looks past the next renewal and focuses on measurable outcomes, human impact, and long-Term ROR.
Why million-dollar therapies create a different kind of cost risk #
Traditional specialty drugs are expensive, but many are paid over time. Gene and cell therapies change that pattern. The claim often lands once, and it lands hard.
That creates a different risk profile. Frequency may stay low, yet severity is extreme. A Self-Funded employer might go years without a case, then face a seven-figure bill in one quarter. The U.S. benefits system is far better built for recurring treatment costs than for one-time cures with prices that can rival capital projects.
This is why leaders can’t treat gene therapy like a larger version of a normal pharmacy claim. The math, the timing, and the funding pressure are different. Plans need a better view of volatility, vendor roles, and member experience. Many of the same issues show up in broader discussions about managing high-cost specialty pharmaceuticals, but gene and cell therapies raise the stakes.
The price is only part of the story #
List price gets attention because it is easy to quote. It is rarely the full bill.
Total episode cost may include pre-treatment testing, hospital or infusion center charges, travel, Case Management, fertility preservation in some settings, complications, and years of follow-up monitoring. Some therapies also require specialized handling, strict Provider selection, and coordination across medical and pharmacy benefits.
The operational impact matters too. HR may need leave coordination. Finance may need to model cash timing. Clinical vendors may need to confirm site of care, prior authorization, and outcomes tracking.
Leaders should price the full episode, not only the drug.
Why a rare claim can still affect the whole plan #
A plan does not need many claims to feel the shock. One case can change renewal talks, Stop-Loss pricing, reserve needs, and year-over-year trend expectations.
Self-Funded employers feel this most clearly. A single therapy may pierce the specific Deductible, change aggregate performance, and bring new scrutiny to plan exclusions. Even fully insured groups can face indirect effects through carrier pricing and tighter underwriting.
That is why rare does not mean minor. When a claim is big enough, the whole plan notices.
How employers can reduce risk without blocking access to care #
The best response is coordinated, not reactive. Payment design, contract review, pharmacy strategy, and employee support need to work together.
The options below are most effective when employers review them before a claim arrives.
Here is a simple way to compare the main approaches:
| Strategy | What it does | Best use |
|---|---|---|
| Value-based contract | Ties payment to treatment outcomes | Reduces waste when long-Term benefit is uncertain |
| Carve-out program | Separates certain therapies from the core plan | Improves predictability for targeted high-cost claims |
| Stop-Loss Insurance | Caps catastrophic exposure for Self-Funded plans | Limits plan shock from a major case |
Each option helps with a different part of the risk. Most employers need a mix.
How value-based contracts tie payment to real outcomes #
A value-based contract means payment depends, at least in part, on whether the therapy performs as promised. In plain English, the employer or payer is not paying only for the dose. They are paying for the expected health outcome.
That can take several forms. A manufacturer may offer a Rebate if the patient does not hit a defined milestone. A payer may spread payments over time. Some agreements include refunds or warranty-like features if the benefit fades too soon.
Public reporting shows outcomes-based arrangements now exist in the market for therapies such as Casgevy, Hemgenix, Kymriah, Luxturna, Lyfgenia, Roctavian, Vyjuvek, Zolgensma, and Zynteglo, even though many deal terms remain private. CMS has also pushed this model forward through its Cell and Gene Therapy Access Model, which points to wider acceptance of outcomes-based payment.
This approach will not remove every cost risk. Still, it can improve fairness. When the therapy misses the mark, the payer should not carry the full burden alone.
When carve-out programs make sense for gene therapy claims #
A carve-out program pulls selected therapies out of the standard medical or pharmacy plan and covers them through a separate arrangement. Employers use carve-outs to gain more control over a small set of very large claims.
Some models are Deductible-based. The employer keeps part of the risk, and the carve-out program steps in after a threshold. Others are full carve-outs, where the dedicated vendor manages eligible therapies from the first dollar.
The appeal is clear. Carve-outs can improve predictability, widen access to specialty clinical review, and create cleaner funding terms for therapies that would otherwise rattle the plan.
However, details matter. Employers should review covered therapy lists, eligibility rules, contract triggers, Provider network requirements, and member handoffs between vendors. A carve-out that saves money on paper can still create friction if employees face delays or confusing instructions.
What Stop-Loss Insurance can and cannot protect #
For Self-Funded employers, Stop-Loss coverage is often the backstop. It limits exposure once a claim crosses the specific attachment point, and it can protect the broader plan from catastrophic loss.
Yet Stop-Loss is not a cure-all. Some policies have gene therapy exclusions. Some carriers apply lasers. Some raise attachment points after a large claim. Others may price terms differently when a carve-out is in place.
Because the details are technical, employers need clean claims review and careful modeling. JA’s actuarial services for stop-loss analysis can help leaders test scenarios before renewal, not after a shock claim changes the conversation.
Stop-Loss reduces the hit. It does not replace governance, forecasting, or vendor oversight.
Where biosimilars can create breathing room in the budget #
Biosimilars do not solve gene therapy pricing. They solve a different problem. That still matters.
When employers save money on high-cost biologics elsewhere in the pharmacy benefit, they create room to absorb pressure from ultra-high-cost therapies. IQVIA has projected about $181 billion in U.S. biosimilar savings from 2023 through 2027. That number gets attention because the opportunity is real, not because biosimilars are a magic fix.
For finance leaders, this is budget relief. For HR, it can support richer affordability strategies. For executive teams, it is a reminder that large-cost risk and savings opportunity often sit in different parts of the plan.
Why biosimilar savings matter even if gene therapies are different #
Biosimilars are follow-on versions of biologic drugs. They are not gene therapies, and they should not be discussed as if they are interchangeable.
Still, every dollar saved in one part of the pharmacy benefit helps fund the whole plan. If a plan lowers spend on biologics with biosimilar competition, that can improve flexibility for Stop-Loss terms, reserve planning, and member cost-sharing choices elsewhere.
That is one reason employers need broad visibility into pharmacy trend, not a narrow view of one headline claim. Better custom employee benefits benchmarking can help leadership teams see where savings are real and where cost pressure is rising.
Simple ways to capture more value from biosimilars #
The work starts with Plan Design and vendor alignment. Employers should review Formulary placement, Rebate strategy, and Provider incentives. If the PBM says biosimilars are preferred, claims data should prove it.
Site-of-care strategy also matters. A lower-cost drug can still become an expensive claim in the wrong setting. In addition, Provider education and member communication help reduce confusion when a biosimilar becomes the preferred option.
Finally, claims analysis should continue all year. Savings targets mean little if uptake stalls or exceptions swallow the gains.
A practical decision framework for C-suite, finance, and HR leaders #
Strong planning starts with listening to each role’s concern. Finance wants funding stability. HR wants a clear member experience. Executives want a strategy that protects people and the business.
The next step is discovery. Review current plan language, vendor contracts, Stop-Loss terms, and pharmacy carve-out rules. Then assess how one therapy claim would flow through the plan from first diagnosis to reimbursement. After that, build the funding model, align communication, and assign ownership for outcomes tracking.
This is also the point where compliance, reporting, and renewal timing matter. Employers should review contract and notice obligations alongside broader annual health plan compliance deadlines, especially when pharmacy benefits and vendor structures are changing.
The goal is simple. Bring the big picture back to the person using the plan, while keeping costs visible and decisions accountable.
Questions leaders should ask before the next renewal #
A short set of questions can sharpen the whole strategy:
- Which gene and cell therapies are covered today, and where are exclusions hiding?
- If one claim hit tomorrow, how would payment flow through the plan, Stop-Loss, and vendors?
- Do current contracts support value-based payment, or do they block it?
- If a carve-out exists, who owns member communication and care coordination?
- Who tracks outcomes, refunds, and performance guarantees after treatment?
Million-dollar therapies do not force employers to choose between cost control and care. They do force better planning.
A sound strategy starts with understanding the real risk, then matching it with value-based payment where possible, careful carve-out review, strong Stop-Loss terms, and savings from biosimilars and smarter pharmacy management. That approach protects budget stability without losing sight of the employee or family behind the claim.
The strongest benefits plans do more than absorb shocks. They create meaningful impact for the business and the people it serves.
